Extended Data Fig. 5: Percentage of patients in each IL-8 subgroup by PD-L1 status (negative or positive) across cohorts. | Nature Medicine

Extended Data Fig. 5: Percentage of patients in each IL-8 subgroup by PD-L1 status (negative or positive) across cohorts.

From: Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

Extended Data Fig. 5

Percentage of patients with baseline serum IL-8 levels <23 pg/ml or ≥23 pg/ml by PD-L1 status (negative [<1%] or positive [≥1%]) in Mel (CheckMate 067 [PD-L1 < 1%, n = 183; PD-L1 ≥ 1%, n = 673; P = 0.296]) (a), RCC (CheckMate 025 [PD-L1 < 1%, n = 514; PD-L1 ≥ 1%, n = 168; P = 0.884]) (b), sqNSCLC (CheckMate 017 [PD-L1 < 1%, n = 85; PD-L1 ≥ 1%, n = 99; P = 0.263]) (c), and nsqNSCLC (CheckMate 057 [PD-L1 < 1%, n = 181; PD-L1 ≥ 1%, n = 224; P = 0.171]) (d). IL, interleukin; Mel, melanoma; nsqNSCLC, nonsquamous non-small cell lung cancer; PD-L1, programmed death-ligand 1; RCC, renal cell carcinoma; sqNSCLC, squamous NSCLC; P, p-value for chi-squared test of independence between IL-8 subgroup (≥23 pg/ml vs < 23 pg/ml) and PD-L1 status (≥1% vs < 1%).

Back to article page